Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and mixed episodes in children aged 10-17 associated with bipolar disorder.
The FDA has given the approval on the basis of four-week-study results. The drug showed effectiveness compared to a placebo.
The drug was first approved on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind in adults.
US President Joe Biden and Iraqi Prime Minister Mustafa Al Qadimi signed an agreement on July 26 to formally end the USA's military presence in the country by the end of the year